NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Collaborating Centre for Women's and Children's Health (UK). Diabetes (Type 1 and Type 2) in Children and Young People: Diagnosis and Management. London: National Institute for Health and Care Excellence (UK); 2015 Aug. (NICE Guideline, No. 18.)
Update information November 2016: Recommendations 123 and 180 have been amended to add information on when eye screening should begin. Please note the date label of [2015] is unchanged, as this is when the recommendation was written and the evidence last reviewed. The changes made in November 2016 are clarifications of the 2015 wording, not new advice written in 2016, so do not carry a [2016] date.
Diabetes (Type 1 and Type 2) in Children and Young People: Diagnosis and Management.
Show details14.1. Optimal HbA1c target
14.1.1. Review question
What is the optimal HbA1c target for children and young people with type 2 diabetes?
14.1.2. Introduction
This was a new topic covered by the 2015 update scope. The objective of this review question is to determine the optimal achievable HbA1c target for children and young people with type 2 diabetes. The review was limited to randomised controlled trials (RCTs) in the first instance. The most important outcomes were agreed a priori to be the worsening or development of long-term complications, and also included:
- hypertension
- retinopathy
- nephropathy
- glycaemic control
- severe hypoglycaemic episodes (including nocturnal hypoglycaemia)
- changes in body mass index (BMI) standard deviation score (SDS)
- health-related quality of life
- satisfaction of children, young people and families with the intervention.
14.1.3. Description of included studies
No studies met the inclusion criteria for this review and no evidence table was generated.
14.1.4. Evidence profile
No studies were identified for this review and so there is no evidence profile.
14.1.5. Evidence statements
No evidence was identified for inclusion in this review.
14.1.6. Health economics profile
A systematic literature search did not identify any relevant economic evaluations addressing optimal HbA1c targets for children and young people with type 2 diabetes.
This review was not prioritised for health economic analysis as a target of itself does not incur an opportunity cost, although the target may affect the choice of interventions used.
14.1.7. Evidence to recommendations
14.1.7.1. Relative value placed on the outcomes considered
The guideline development group had hoped to find evidence to determine the optimal HbA1c target for children and young people with type 2 diabetes to minimise the risk of long-term complications without incurring an increase in hypoglycaemic episodes. In particular, the group had hoped to find evidence related to the following long-term complications: hypertension; retinopathy; and nephropathy. The group also hoped to find evidence related to glycaemic control and changes in BMI SDS. They group wished to know whether there was any impact on psychosocial outcomes including health-related quality of life and the satisfaction of hildren, young people and families with treatment.
14.1.7.2. Consideration of clinical benefits and harms
The group was aware that the NICE guideline on type 2 diabetes in adults recommended a target level for HbA1c of 6.5% or less to minimise the risk of long-term complications. The group considered whether this would also be an appropriate target for children and young people with type 2 diabetes. It was noted that if the target was set at an unachievably low level, this would lead to children and young people disengaging with the process of effective HbA1c monitoring. In addition, the group did not wish to set a target that was so low that, were it to be achieved, it would increase the risk of hypoglycaemia. However, it was felt important to set an aspirational target which would have a meaningful effect on the child or young person's long-term health. If the target HbA1c level was set too high, the guideline development group felt that children and young people would be less likely to drive themselves to achieving even lower targets for HbA1c.
Ultimately, the group agreed that 6.5% was an appropriate target for children and young people as it was a safe target that was also aspirational without risking being unachievable. As was the case for the HbA1c target for children and young people with type 1 diabetes, the guideline development group expressed the target HbA1c value in IFCC units (48 mmol/mol).
The group recognised that for some children and young people with type 2 diabetes the specified target for HbA1c may be unattainable. Although efforts should be made towards the ideal HbA1c target, the group's clinical experience suggested that any reduction in HbA1c would be associated with a decreased risk of long-term complications and this would be of clinical benefit. However, the group considered that setting the lowest attainable target of HbA1c should be an a priori decision based on the child or young person's individual circumstances, recognising the important role of support from healthcare professionals towards achieving this aim.
14.1.7.3. Consideration of health benefits and resource use
Achieving a target may have opportunity costs both in terms of the interventions and actions required to improve glycaemic control. The guideline development group recognised that any reduction towards the normal range would improve long-term outcomes for children and young people with type 2 diabetes and thereby reduce the chance of further treatment being required. There was a lack of evidence for a specific HbA1c target in children and young people with type 2 diabetes. The group also felt that the target they had recommended was not so low as to increase the risk of hypoglycaemic episodes. Given this, they agreed that the target for HbA1c of 6.5% was very likely to be cost effective.
14.1.7.4. Quality of evidence
No relevant studies were identified for this review question and so the group relied on other NICE guidance in conjunction with their clinical and patient experience to make recommendations.
14.1.7.5. Other considerations
The group agreed that when setting targets for achieving outcomes with children and young people, it is extremely important to be supportive and encouraging. They noted that for some children and young people it would be extremely difficult to achieve a target HbA1c of 6.5% and so any form of reduction should be praised as the reduction would have some benefit for the future health of the child or young person.
Although the review question did not specifically address the frequency at which HbA1c monitoring should be performed, there was a recommendation in the 2004 guideline about the frequency at which HbA1c monitoring should be performed in children and young people with type 1 diabetes. The group agreed that it would be appropriate to specify the frequency of HbA1c monitoring for type 2 diabetes and hence, based on their clinical and patient experience, they agreed that a 3-monthly schedule for measuring the HbA1c level of the child or young person would be reasonable.
14.1.7.6. Key conclusions
The guideline development group concluded that a strong recommendation to measure HbA1c every 3 months in children and young people with type 2 diabetes, and to aim for an HbA1c level of 48 mmol/mol (6.5%) or lower, was warranted. The group specifically recommended that healthcare professionals should agree an individualised lowest achievable HbA1c target with each child or young person with type 2 diabetes and their family members or carers (as appropriate), taking into account factors such as daily activities, individual life goals, complications and comorbidities.
The group also mirrored several recommendations related to the HbA1c target for children and young people with type 1 diabetes, including those related to:
- calibrating HbA1c results according to IFCC standardisation
- explaining that an HbA1c target level of 48 mmol/mol (6.5%) or lower is ideal to minimise the risk of long-term complications
- explaining that any reduction in HbA1c level reduces the risk of long-term complications
- diabetes services documenting the proportion of children and young people who achieve an HbA1c level of 53 mmol/mol (7%) or lower.
14.1.8. Recommendations
- 150.
Use methods to measure HbA1c that have been calibrated according to International Federation of Clinical Chemistry (IFCC) standardisation. [new 2015]
- 151.
Explain to children and young people with type 2 diabetes and their family members or carers (as appropriate) that an HbA1c target level of 48 mmol/mol (6.5%) or lower is ideal to minimise the risk of long-term complications. [new 2015]
- 152.
Explain to children and young people with type 2 diabetes who have an HbA1c level above the ideal target of 48 mmol/mol (6.5%) and their family members or carers (as appropriate) that any reduction in HbA1c level reduces the risk of long-term complications. [new 2015]
- 153.
Explain the benefits of safely achieving and maintaining the lowest attainable HbA1c to children and young people with type 2 diabetes and their family members or carers (as appropriate). [new 2015]
- 154.
Agree an individualised lowest achievable HbA1c target with each child or young person with type 2 diabetes and their family members or carers (as appropriate), taking into account factors such as daily activities, individual life goals, complications and comorbidities. [new 2015]
- 155.
Measure HbA1c levels every 3 months in children and young people with type 2 diabetes. [new 2015]
- 156.
Support children and young people with type 2 diabetes and their family members or carers (as appropriate) to safely achieve and maintain their individual agreed HbA1c target level. [new 2015]
- 157.
Diabetes services should document the proportion of children and young people with type 2 diabetes in a service who achieve an HbA1c level of 53 mmol/mol (7%) or lower. [new 2015]
- Management of type 2 diabetes – targets for and monitoring of glycaemic control ...Management of type 2 diabetes – targets for and monitoring of glycaemic control - Diabetes (Type 1 and Type 2) in Children and Young People
- Microbacterium lemovicicum strain Viu22 chromosome, complete genomeMicrobacterium lemovicicum strain Viu22 chromosome, complete genomegi|1547497929|ref|NZ_CP031423.1|Nucleotide
- Microbacterium lemovicicum strain ViU22 16S ribosomal RNA, partial sequenceMicrobacterium lemovicicum strain ViU22 16S ribosomal RNA, partial sequencegi|645321256|gnl|REF_SSU16S|JN24335 400|ref|NR_118267.1|Nucleotide
- Sargassum sp. voucher PHLR7B small subunit ribosomal RNA gene, partial sequence;...Sargassum sp. voucher PHLR7B small subunit ribosomal RNA gene, partial sequence; internal transcribed spacer 1 and 5.8S ribosomal RNA gene, complete sequence; and internal transcribed spacer 2, partial sequencegi|1268244924|gb|MG230650.1|Nucleotide
- Salmonella enterica VII 40:z4,z24:-- strain SGSC3121 phase 1 flagellin (fliC) ge...Salmonella enterica VII 40:z4,z24:-- strain SGSC3121 phase 1 flagellin (fliC) gene, complete cdsgi|50830957|gb|AY649737.1|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...